🔗 Share this article

The recently developed medications for gonorrhoea in decades are being hailed as a "significant breakthrough" in the battle against superbug strains of the infection, according to scientists.

A Global Public Health Issue

The sexually transmitted infection are on the rise around the world, with figures suggesting in excess of 82 million new cases annually. Particularly high rates are seen in the African continent and nations within the WHO's designated area, which includes China and Mongolia to New Zealand. Within England, cases have reached a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary step in the reality of increasing worldwide cases, escalating drug resistance and the extremely scarce therapeutic options currently available.”

Medical experts are deeply concerned about the surge in drug-resistant strains. The World Health Organization has listed it as a "critical concern". A tracking program revealed that the effectiveness of primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Therapies Gain Authorization

One new antibiotic, marketed under the name a brand name, was cleared by the US FDA in mid-December for treating gonorrhoea. This disease can lead to serious health problems, including infertility. Scientists anticipate that targeted use of this new drug will help hinder the spread of drug resistance.

Gepotidacin, created by the drugmaker GSK, gained clearance in close succession. This medication, which is employed against urinary tract infections, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

This new treatment emerged from a innovative non-profit model for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to see it through.

“This approval marks a huge turning point in the treatment of highly resistant gonorrhoea, which previously has been staying ahead of medical innovation.”

Clinical Trial Data and Worldwide Availability

According to data detailed in a major medical journal, zoliflodacin cured the vast majority of cases of the STI. This puts it on an equal footing with the current standard treatment, which combines an injection and a pill. The study enrolled nearly 1,000 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the rights to register and commercialise the drug in numerous regions with limited resources.

Doctors on the front lines have expressed positive views. Access to a one-pill regimen such as this is described as a "revolutionary step" for managing the epidemic. This is viewed as crucial to alleviate the strain of the illness for patients and to stop the proliferation of untreatable gonorrhoea around the world.